Understanding skin-related side effects of cancer immunotherapy

Predictive modeling of cutaneous immune checkpoint inhibitor toxicities

NIH-funded research Massachusetts General Hospital · NIH-11045671

This study is looking at skin problems that some cancer patients might experience while getting immune checkpoint inhibitors, with the goal of understanding how common these issues are and what might cause them, so we can help patients feel better and keep up with their important treatments.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionMassachusetts General Hospital NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-11045671 on NIH RePORTER

What this research studies

This research investigates the skin-related toxicities that can occur in patients receiving immune checkpoint inhibitors (ICIs) for cancer treatment. It aims to identify the frequency and types of these skin reactions, known as cutaneous immune-related adverse events (cirAEs), and the factors that contribute to their development. By analyzing real-world data, the study seeks to improve patient outcomes by understanding how these side effects impact treatment and quality of life. The findings could help in developing strategies to mitigate these adverse effects and ensure patients can continue their life-saving cancer therapies.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients undergoing treatment with immune checkpoint inhibitors for cancer who may experience skin-related side effects.

Not a fit: Patients not receiving immune checkpoint inhibitors or those without skin-related adverse events may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to better management of skin toxicities, allowing patients to receive effective cancer treatment without significant interruptions.

How similar studies have performed: Previous research has shown that understanding adverse effects of cancer therapies can lead to improved patient management, indicating potential success for this approach.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer therapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.